The Allstate Corporation

New York Stock Exchange
Slightly Bullish +25

Allstate Corporation

πŸš€ ALL stock trades near its 52-week high, rising 1.04% since last market close.

🏦 Allstate Corp operates in property and casualty insurance across multiple segments including auto, homeowners, and commercial lines.

βš–οΈ The company was founded in 1931 and is headquartered in Northbrook, Illinois.

πŸ“Š Total revenue reached $67.69 billion for the year and $17.34 billion for the fourth quarter.

πŸ“ˆ Net income surged 120.31% year-over-year while EPS jumped 123.99% during the same period.

⚠️ Analyst opinions are mixed, with Mizuho lowering its price target and Barclays maintaining a Sell rating.

πŸ’° Goldman Sachs raised its price target to $238 from $227 and Wells Fargo increased its target to $228.

πŸ”’ Allstate is facing a privacy lawsuit regarding the tracking of drivers on cellphones.

πŸŒͺ️ The company reported January catastrophe losses of $140 million to $175 million in various updates.

πŸ›‘οΈ Business segments include Protection, Protection Services, Health and Benefits, Run-off Property-Liability, and Corporate/Other.

βš–οΈ KBW maintains a Buy rating despite other firms holding neutral or conflicted positions on the stock.

πŸ“‰ Some analysts are bearish while others remain bullish, reflecting market uncertainty in the financial sector.

Bullish Signals
  • Allstate Corporation (ALL) is trading near the top of its 52-week range and above its 200-day simple moving average, indicating strong technical momentum.
  • The stock price has risen $2.17 since market close, representing a 1.04% gain in regular hours.
  • After-hours trading saw an additional $1.47 increase in the stock price, further supporting bullish sentiment.
  • Net Income surged by 120.31% year-over-year and EPS increased by 123.99%, demonstrating significant profitability growth.
  • Revenue for the last year reached $67.69 billion with a 5.58% increase compared to the prior year.
  • Goldman Sachs raised its price target to $238 from $227, signaling positive analyst outlook.
  • JPMorgan increased its price target to $263 from $260, showing confidence in Allstate's growth potential.
  • Piper Sandler upgraded Allstate to a Buy rating, reflecting favorable sentiment among major financial institutions.
  • Keefe Bruyette raised the price target to $260 from $254, indicating continued upside expectations.
  • Citi increased its price target to $221 from $216, further validating positive market positioning.
Risk Factors
  • Allstate received a price target lowered to $265 from $281 at Mizuho, indicating negative sentiment from the analyst firm.
  • The stock was downgraded to Neutral from Buy by Goldman Sachs and also received a Hold rating from TD Cowen and Morgan Stanley.
  • Barclays maintained its Sell Rating for Allstate, contrasting with some other bullish upgrades.
  • Allstate faces a privacy lawsuit regarding the cellphone tracking of drivers as reported by Reuters.
  • The company experienced January catastrophe losses of $140M and subsequently another report showed $175M in catastrophe losses, impacting earnings.
  • Total revenue held flat since last quarter despite a year-over-year increase, suggesting limited growth momentum in the recent period.
  • Analysts remain conflicted on Allstate with opinions mixed alongside competitors like Primerica.
  • The stock price has risen significantly but faces volatility as broader markets react to macro concerns like oil prices and geopolitical tensions.
Full Analysis
Allstate Corporation (ALL) is currently trading near the top of its 52-week range and above its 200-day simple moving average, reflecting mixed market sentiment despite a recent price increase. Shares have risen $2.17 since the previous market close, representing a 1.04% rise, with an additional $1.47 gain observed in after-hours trading. The company operates within the property and casualty insurance sector through multiple segments including Allstate Protection, which covers private passenger auto, homeowners, and commercial insurance under brands like Allstate and National General; Allstate Health and Benefits, offering voluntary benefits and life insurance products; and others focused on protection services and run-off claims related to asbestos and environmental exposures. Founded in 1931 and headquartered in Northbrook, IL, Allstate is classified as a large capitalization company with a market cap between $10 billion and $200 billion. Analyst opinions regarding Allstate remain conflicted, with a range of rating adjustments reflecting divergent views on the stock's future performance. Recent activity includes Mizuho lowering its price target to $265 from $281 and TD Cowen issuing a Hold rating, while Goldman Sachs downgraded the stock to Neutral. Conversely, several firms have raised their price targets or upgraded ratings; Keefe Bruyette increased its target to $260 from $254, Mizuho raised its price target back to $281 from $255, Citi boosted its target to $221 from $216, Wells Fargo adjusted its target upward to $228 from $223, Goldman Sachs raised its price target to $238 from $227, and Piper Sandler assigned a Buy rating. JPMorgan also increased its price target to $263 from $260. Despite these mixed signals, KBW maintains its Buy rating for Allstate, and Barclays retains its Sell rating. Financial performance data highlights significant growth in certain metrics over the past year while Q4 figures remain steady compared to the previous quarter. Total revenue is reported at $67.69 billion on a one-year basis and $17.34 billion in the fourth quarter, with revenue increasing 5.58% since last year but holding flat since the last quarter. Net income showed substantial growth, rising 120.31% since last year and holding flat for the quarter, while earnings per share reached $38.06 on a one-year basis and $14.37 in Q4, representing a 123.99% increase year-over-year. Operational updates from Allstate also disclosed January catastrophe losses of $140 million in one report and $175 million in another, alongside monthly estimates for policy growth.